The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
REGULATORY
GSK’s Blenrep, Moderna RSV Jab Edge Closer to Japan Approval with Panel OK
A Japanese health ministry panel on April 21 gave the thumbs-up for approving a list of new medicines and label expansions including GlaxoSmithKline’s antibody drug conjugate (ADC) belantamab mafodotin and Moderna’s respiratory syncytial virus (RSV) vaccine. Known with the brand…
To read the full story
Related Article
- Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
- New Usages of Anaemetro, Raiatt Now Eligible for Health Coverage
April 23, 2025
- MHLW Panel to Review Moderna’s RSV Jab, GSK’s ADC, and More on April 21
April 14, 2025
- MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
- GSK’s Multiple Myeloma Drug Blenrep Filed in Japan
September 18, 2024
- MSD Files Keytruda for Malignant Pleural Mesothelioma in Japan
July 2, 2024
- Moderna Submits RSV Vaccine in Japan
May 31, 2024
REGULATORY
- New Skipper of PMDA’s Review Center Wears Multiple Hats to Push Fight against Drug Loss
June 2, 2025
- LDP Group Urges Ministers to Keep Coverage of Pain Relief Patches
June 2, 2025
- PMDA Reviewing Safety Risks of Thiamazole, Desmopressin
June 2, 2025
- Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
May 30, 2025
- Regulatory Reform Panel Calls for Review of Clinical Trial Ad Rules
May 30, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…